Figure 1.
Prevalence and distribution of standardised molecular Minimal Residual Disease (MRD) targets in adults >65 years entering the National Cancer Research Institute (NCRI) Acute Myeloid Leukemia (AML)-16 trial [47].
Prevalence and distribution of standardised molecular Minimal Residual Disease (MRD) targets in adults >65 years entering the National Cancer Research Institute (NCRI) Acute Myeloid Leukemia (AML)-16 trial [47].